Lupin Ltd

Lupin Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (INR)640.00
  • Today's Change-8.55 / -1.32%
  • Shares traded721.97k
  • 1 Year change-17.12%
  • Beta0.6470
Data delayed at least 15 minutes, as of Mar 24 2023 10:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lupin Limited is an India-based pharmaceutical company. The Company develops and commercializes a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in over 100 markets in the United States, India, South Africa, and across the Asia Pacific, Latin America, and others. It offers vitamins, minerals, supplements and neurological products. It has presence in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and nonsteroidal anti-inflammatory drug therapy segments. Its complex generics portfolio includes Filgrastim, Peg-Filgrastim, Etanercept and Albuterol, and others. Its biosimilar products include Filgrastim, Peg-Filgrastim and Etanercept. Its specialty products consist of Solosec and NaMuscla. Its over-the-counter products include Softovac, Lupizyme, Aptivate, Lupisafe, Be One and V-Bath, and others. It supplies APIs for anti-retroviral, anti-malarial and others.

  • Revenue in INR (TTM)160.95bn
  • Net income in INR-3.24bn
  • Incorporated1983
  • Employees19.79k
  • Location
    Lupin LtdB/4 Laxmi Towers, Bandra Kurla Complex, Bandra (E)MUMBAI 400051IndiaIND
  • Phone+91 2 266402222
  • Fax+91 2 266402130
  • Websitehttp://www.lupin.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
Boehringer Ingelheim International GmbH-Ondero & Ondero Met BrandsAnnounced24 Aug 202224 Aug 2022Announced-8.37%--
Data delayed at least 15 minutes, as of Mar 24 2023 10:21 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
J B Chemicals and Pharmaceuticals Ltd30.12bn4.07bn151.51bn4.34k37.45--29.595.0352.2952.29386.99--------6,939,050.00--14.74--17.4763.2759.8313.5315.46--23.30--29.5718.6912.20-13.9815.9335.2575.18
Ajanta Pharma Ltd37.31bn6.17bn156.42bn7.23k25.43--20.974.1948.0148.01290.34--------5,157,714.00--17.70--21.0771.8975.7016.5420.68------15.3515.6210.798.997.05-13.03-6.08
Piramal Enterprises Ltd104.23bn102.74bn159.99bn13.56k1.57--1.511.53430.44430.44436.59--------7,686,321.00--2.44--3.4062.8082.3598.9615.05--1.45--30.489.2410.3644.348.96-15.0910.12
Pfizer Limited24.02bn6.20bn161.28bn2.29k26.01--22.056.72135.52135.52524.87--------10,511,070.00--12.76--16.5364.7260.6825.8221.77--46.21--84.0516.645.0423.1012.71-9.5518.47
Laurus Labs Ltd60.84bn9.18bn164.40bn5.13k17.93--13.432.7017.0217.02112.84--------11,858,270.00--11.29--19.6554.5947.9515.1413.77--9.94--11.742.5420.64-15.8734.1825.8746.14
IPCA Laboratories Ltd60.22bn5.25bn198.61bn15.16k37.84--24.963.3020.6920.69237.30--------3,973,468.00--12.86--16.6664.4459.869.0114.45--18.13--10.267.5612.67-22.4535.3628.5751.57
Gland Pharma Ltd39.43bn9.89bn205.17bn4.64k20.79--18.185.2059.9159.91239.01--------8,498,823.00--------52.67--25.07----146.39----27.08--21.54------
GlaxoSmithKline Pharmaceuticals Limited32.74bn4.20bn217.37bn3.84k51.82--44.976.6424.76100.12193.23--------8,525,779.00--8.78--13.9560.5553.7312.8110.19--519.35--212.5312.051.7932.552.48-35.2514.87
Syngene International Ltd29.57bn4.33bn230.41bn5.98k52.91--29.377.7910.9010.9074.13--------4,948,285.00--9.20--12.6673.5870.6314.6618.41--7.95----19.2216.74-2.256.629.190.00
Biocon Ltd98.09bn3.88bn243.14bn3.20k62.94--16.502.483.243.2481.89--------30,624,730.00--5.67--7.8666.7460.435.2212.71--3.17--5.2314.5715.85-12.441.1620.360.00
Aurobindo Pharma Ltd241.92bn19.98bn280.52bn21.00k14.05--8.901.1634.0934.09412.78--------11,519,900.00--11.53--18.3055.0053.958.2614.54--39.07--6.66-5.329.22-50.362.849.8129.20
Lupin Ltd160.95bn-3.24bn299.76bn19.79k----47.011.86-7.15-7.15353.59--------8,133,110.00--0.0772--0.108158.6161.21-1.900.1267--5.03--2,376.128.19-1.28-225.61---19.25-11.81
Alkem Laboratories Ltd111.81bn10.21bn384.19bn16.97k37.64--28.203.4485.3885.38935.18--------6,589,957.00--12.30--18.1958.1259.279.3714.07--11.59--25.5819.9612.693.8213.03-12.0717.78
Data as of Mar 24 2023. Currency figures normalised to Lupin Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

26.72%Per cent of shares held by top holders
HolderShares% Held
Life Insurance Corporation of India (Investment Portfolio)as of 31 Mar 202238.12m8.38%
ICICI Prudential Asset Management Co. Ltd.as of 19 May 202223.07m5.07%
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 28 Feb 202318.30m4.02%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 28 Feb 20238.75m1.92%
The Vanguard Group, Inc.as of 03 Mar 20237.57m1.66%
Norges Bank Investment Managementas of 31 Mar 20226.05m1.33%
BlackRock Fund Advisorsas of 01 Mar 20235.50m1.21%
SBI Funds Management Pvt Ltd.as of 28 Feb 20235.11m1.12%
DSP Investment Managers Pvt. Ltd.as of 28 Feb 20234.62m1.02%
HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 28 Feb 20234.49m0.99%
More ▼
Data from 31 Dec 2022 - 16 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.